Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)

South Korea · Delayed Price · Currency is KRW

4,115.00

+105.00 (2.62%)

At close: Jul 31, 2026

Seoulin Bioscience Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	78,585	77,091	75,410	89,569	104,708	80,539
Revenue Growth	5.38%	2.23%	-15.81%	-14.46%	30.01%	23.74%
Gross Profit	17,203	17,282	18,961	19,871	24,292	21,070
Operating Income	769.1	691.62	952.67	2,495	9,198	7,451
Net Income	518.17	731.98	2,914	-117.55	10,159	15,589
Earnings Per Share	32.77	55.00	335.00	-13.11	780.07	1732.89
EPS Growth	-89.60%	-83.58%	-	-	-54.98%	218.90%

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	34,823	34,716	23,510	35,414	55,280	75,332
Total Debt	11,885	11,580	3,680	6,714	17,785	15,738
Net Cash (Debt)	22,939	23,137	19,830	28,700	37,495	59,594
Net Cash Growth	7.20%	16.68%	-30.91%	-23.46%	-37.08%	211.92%
Net Cash Per Share	2376.24	2400.48	2279.74	3201.94	3369.03	6625.03

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	1,358	4,760	-4,611	930.57	-4,356	8,918
Capital Expenditures	-382.44	-392.61	-48.45	-945.51	-461.62	-933.29
Free Cash Flow	975.2	4,367	-4,660	-14.95	-4,817	7,984
Free Cash Flow Growth	-	-	-	-	-	143.19%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	21.89%	22.42%	25.14%	22.18%	23.20%	26.16%
Operating Margin	0.98%	0.90%	1.26%	2.79%	8.78%	9.25%
Pretax Margin	0.83%	1.15%	4.71%	-2.15%	13.40%	25.25%
Profit Margin	0.66%	0.95%	3.86%	-0.13%	9.70%	19.36%
FCF Margin	1.24%	5.67%	-6.18%	-0.02%	-4.60%	9.91%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	125.59	78.50	21.09	-	9.60	11.21
Forward PE	-	19.70	19.70	19.70	19.70	19.70
P/FCF Ratio	38.11	13.16	-	-	-	21.89
PS Ratio	0.47	0.75	0.82	0.88	0.93	2.17